Industry News · Prescribing Options
A trusted flower,
now in a new form
Bedrocan® — the world’s most prescribed pharmaceutical cannabis flower — is set to become available as a standardised extract concentrate for the first time. For patients, that could mean the same trusted medicine available in more ways than ever before.
years of Bedrocan® pharmaceutical cannabis production trusted by doctors worldwide
THC concentration in the new Becanex PIEX Bedrocan® extract — preserving the full cannabinoid and terpene fingerprint
preparation formats now possible from a single standardised concentrate, from capsules to inhalation
Target launch date for pharmacy ordering across Europe, with Germany as the first market
The Bedrocan® flower you know — in concentrated form
If you have been prescribed Bedrocan® flower, you will know it as one of the most consistent and well-studied pharmaceutical cannabis products available. Grown in EU-GMP-certified facilities in the Netherlands and Denmark by Bedrocan International, it has been the benchmark for standardised medical cannabis for more than two decades.
Now, that same product is set to take a new form. Berlin-based extraction specialist Becanex GmbH has developed the Becanex PIEX Bedrocan® 70% THC Concentrate — an extract that, for the first time, brings the full cannabinoid and terpene fingerprint of the Bedrocan® flower into a standardised, pharmacist-ready concentrate.
The extract is produced using Becanex’s proprietary PIEX (Plant-Identical Extraction) process, which is specifically designed to preserve what makes a particular cannabis strain therapeutically distinctive. In simpler terms: this is not a generic cannabis extract. It is Bedrocan® in a bottle — the same profile, in a versatile new format.
What makes it different from other extracts?
Many cannabis extracts are produced to isolate one or two cannabinoids — often just THC or CBD — and discard the rest. The PIEX method takes a different approach, retaining the full spectrum of naturally occurring cannabinoids and terpenes in proportions that match the original flower. Becanex describes this as “a fingerprint” of the source material, and that precision matters clinically: the interaction between cannabinoids and terpenes — sometimes called the entourage effect — is increasingly recognised as relevant to therapeutic outcomes.
The result is a concentrate that is both highly potent (at 70% THC) and pharmacologically familiar to doctors and pharmacists who have already been prescribing Bedrocan® flower.
“We have always been precise about how we grow our cannabis. Becanex is equally precise about how they extract it. That shared attention to detail is what makes this product worth putting in front of pharmacists, prescribers and patients. The concentrate now enables doctors to prescribe our main product Bedrocan® in multiple compounding formulations.”
Jaap Erkelens — CEO, Bedrocan International
More ways for pharmacists to prepare your medicine
One of the most significant implications of this product for patients is flexibility. A standardised concentrate that sits in a pharmacy’s dispensary can be compounded into a wide range of preparation formats, tailored to what works best for each individual. The Becanex PIEX Bedrocan® concentrate is specifically designed for the following preparations:
Oral solution
Capsules
Suppositories
Topical forms
Inhalation dosage
Vaporisation
What this means in practice for patients
For patients currently prescribed Bedrocan® flower, this is particularly significant. If inhalation becomes difficult — whether due to respiratory concerns, lifestyle factors, or simply personal preference — a concentrated extract from the same strain could potentially be offered as an oral or capsule-based alternative, without switching to an entirely different product.
The vaporisation option is also noteworthy: the concentrate can be vaporised directly, giving patients an additional inhalation route alongside the flower. This kind of flexibility within a single, consistent product profile is exactly the kind of development that helps both patients and prescribers make evidence-informed adjustments over time.
It is important to note that any change to your prescription formulation must always be discussed with and authorised by your prescribing specialist. The availability of a new format does not mean your prescription changes automatically — it expands the options your clinician can consider for you.
“Patients who have found a cannabis strain that works well for them shouldn’t have to compromise if they need it in a different form. With Bedrocan as our partner, we can now offer prescribers exactly that — building on a strain they already know and trust.”
Sebastian Kamphorst — Director, Becanex GmbH
Why standardisation matters for patients
Consistency you can rely on
One of the greatest frustrations for patients on prescribed cannabis is variability. A standardised extract — manufactured under GMP conditions from a named, controlled cultivar — reduces that uncertainty. You and your prescriber know what to expect.
No need to start from scratch
For patients and doctors who have already found that Bedrocan® works, this product preserves that relationship. Switching formulation format does not mean re-establishing which strain or cannabinoid profile is therapeutically appropriate.
Pharmacist flexibility
Compounding pharmacies are central to how many patients receive their prescribed cannabis. A concentrate designed specifically for compounding gives pharmacists more tools to prepare bespoke preparations that suit individual clinical needs.
Germany first, Europe next
Germany is the first market for the launch, which reflects its position as the most developed regulated medical cannabis market in Europe. UK patients should watch this development closely — it signals the direction of travel for product diversity across Europe.
A decade in the making
This collaboration is not simply a commercial arrangement — it has roots going back more than ten years. As early as 2014, the founding team behind Becanex worked with Bedrocan under a scientific licence to develop the first extracts from the Bedrocan® flower. At the time, the regulatory framework to bring such a product to market did not exist. Today, it does.
Kamphorst reflects on this directly: the team is not reinventing the science — they are returning to it with the regulatory infrastructure finally in place to bring it to patients properly. That history gives the product a credibility that purely commercial partnerships often lack.
Both companies will present the Becanex PIEX Bedrocan® concentrate publicly for the first time at two back-to-back industry events in the same week: Cannabis Europe in London and the Medical Cannabis Conference in Berlin. PatientsCann UK will be keeping a close eye on what emerges.
Key dates to know
2014
Original collaboration begins
Becanex co-founder Eral Osmanoglou works with Bedrocan under a scientific licence to develop the first extracts from the Bedrocan® flower. Regulatory pathways are not yet in place for commercialisation.
19 May 2026
Partnership announced publicly
Bedrocan and Becanex announce the long-term commercial partnership and the Becanex PIEX Bedrocan® 70% THC Concentrate. Germany confirmed as first market.
Week of 25 May 2026
Public debut at Cannabis Europe (London) & Medical Cannabis Conference (Berlin)
Both companies present the joint product for the first time at two consecutive industry events in the same week. The first public demonstration of the concentrate.
Summer 2026
Pharmacy ordering opens
The Becanex PIEX Bedrocan® 70% THC concentrate becomes available to order for pharmacies via Becanex customer service. Product information and technical documentation available on request from either company immediately.
Questions about your prescription options?
PatientsCann UK is a patient-led Community Interest Company. If developments like this raise questions about your current prescription — or about accessing prescribed cannabis for the first time — our free resources can help you understand your options and prepare for a clinical conversation.
This article is based on a press release issued jointly by Bedrocan International and Becanex GmbH on 19 May 2026. PatientsCann UK has not independently verified product claims and has no commercial relationship with either company. This content is for information and education only. It does not constitute medical advice. Any change to your prescribed cannabis formulation must be agreed with your prescribing specialist. The Becanex PIEX Bedrocan® concentrate is not currently available to UK patients via NHS or private prescription routes, availability and regulatory status will vary by country and over time. PatientsCann UK does not endorse any specific product or manufacturer.
Written By
PatientsCann UK
PatientsCann UK® · Industry News · 19 May 2026
PatientsCann UK is a patient-led Community Interest Company (CIC). All content is produced for educational purposes.
<p>The post Bedrocan May 2026 Press Release first appeared on PatientsCann UK®.</p>
